Fertility Preservation Presentation by Dr. Hananel Holzer


Published on

Published in: Health & Medicine
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Fertility Preservation Presentation by Dr. Hananel Holzer

  1. 1. Hananel Holzer, MD Medical Director, MUHC Reproductive Center McGill University Health Center Assistant Professor, Dept. of Obstetrics & Gynecology McGill University McGill University McGill University Health Centre
  2. 2. A comprehensive approach for fertility preservation
  3. 3. Fertility preservation <ul><li>713,220 new cases of female cancer were diagnosed in 2009 in the U.S. (Jemal 2009) </li></ul><ul><li>Childhood cancers 1%. 122 new cases per million children (Skinner 2006) </li></ul><ul><li>By 2010, one in 250 people will be a cancer survivor (Blatt 1999) </li></ul><ul><li>80% of children and adolescents diagnosed with cancer become long-term survivors </li></ul><ul><li>One of long-term side-effects of cancer therapy is premature gonadal failure – infertility </li></ul>
  4. 4. Ovarian reserve <ul><li>Females born with a finite pool of oocytes ( Zukerman 1951) </li></ul><ul><li>Challenged by Johnson, Tilly et al; 2004, 2005; Germ line stem cells </li></ul>
  5. 5. Ovarian reserve W. Hamish B. Wallace 2010
  6. 6. Ovarian reserve W. Hamish B. Wallace 2010
  7. 7. Ovarian reserve W. Hamish B. Wallace 2010
  8. 8. <ul><li>loss of primordial follicles </li></ul><ul><li>ovarian atrophy </li></ul>Chemotherapy
  9. 9. Primordial Follicle Count ⇩⇩⇩ Ovarian Reserve ⇩⇩⇩ Early Menopause and Infertility
  10. 10. <ul><li>The effect of chemotherapy on the ovary is not “ all or none ” </li></ul><ul><li>No. of surviving primordial follicles following exposure correlates inversely to dose of chemotherapy </li></ul>(p = 0.0001) (Meirow et.al. Hum Reprod 1999) 0 500 1000 1500 2000 2500 0 20 50 75 100mg/kg Dose of Cyclophosphamide Number of PMF’s
  11. 11. control chemotherapy Apoptosis TUNEL staining of PMF in human ovaries
  12. 12. <ul><li>Thickening and diffuse hyalinization of vessel wall with luminal narrowing </li></ul>Vascular damage Exposed Not exposed
  13. 13. <ul><li>Focal ovarian cortical fibrosis </li></ul><ul><li>No follicles in zone of fibrosis </li></ul>(Meirow et al. Hum Reprod 2007) Cortical fibrosis
  14. 14. Apoptosis Vascular injury Cortical fibrosis Chemotherapy: Direct and indirect damage cortex medulla
  15. 15. Chemotherapy <ul><li>Alkylating agents: </li></ul><ul><ul><li>Cyclophosphamide,ifosfamide, nitrosoureas, chlorambucil, melphalan, and Busulphan </li></ul></ul><ul><ul><li>not cell-cycle specific, highest risk of ovarian failure. </li></ul></ul><ul><li>Antimetabolites </li></ul><ul><ul><li>methotrexate, bleomycin, 5-fluorouracil, actinomycin-D, mercaptopurine, vincristine) </li></ul></ul><ul><ul><li>impact the cells of the metabolically active ovarian follicles , are considered to be low risk for gonadal dysfunction </li></ul></ul><ul><li>Cisplatin - intermediate risk </li></ul>
  16. 16. chemotherapy <ul><li>Women >40 years have a 90% chance of amenorrhea subsequent to multi-agent chemotherapy </li></ul><ul><li>younger patients 20% - 90%. </li></ul><ul><li>All patients exposed to chemotherapy might have a diminished ovarian reserve </li></ul><ul><li>significant predisposition for developing premature ovarian failure. Infertility > 40% @ 35 years. </li></ul><ul><li>The estimated probability of early menopause was at least 25% at age 30 years and increased significantly with younger age at diagnosis (Letourneau , Cancer 2011) </li></ul>
  17. 17. Radiotherapy <ul><li>Direct damage to ovaries </li></ul><ul><li>Damage to hypothalamic-pituitary axis </li></ul><ul><li>Dose dependent; total dose and fractionation schedule </li></ul><ul><li>Age dependent; size of primordial follicle pool </li></ul><ul><li>Radiation field dependent </li></ul><ul><li>Could also affect uterine function (M/C, IUGR) </li></ul>
  18. 18. Radiotherapy <ul><li>for a given dose of radiation, the younger patients are, the later the onset of premature menopause. </li></ul><ul><li>LD50 <2 Gy. </li></ul><ul><li>the effective sterilising dose falls with increasing age </li></ul><ul><li>effective sterilising doses are 20·3 Gy at birth, 18·4 Gy at 10 years, 16·5 Gy at 20 years, and 14·3 Gy at 30 years. </li></ul><ul><li>model to reliably predict the age of ovarian failure after treatment with a known dose of radiotherapy. ( W Hamish B Wallace, Lancet 2005, International Journal of Radiation Oncology*Biology*Physics 2005 ) </li></ul>
  19. 19. Fertility preservation
  20. 20. Fertility preservation <ul><li>Indications: </li></ul><ul><li>Cancer patients before gonadotoxic treatment </li></ul><ul><li>Other diseases before gonadotoxic treatment </li></ul><ul><li>Young patients with Turner syndrome, Fragile X premutation (FMR 1), Galactosemia </li></ul><ul><li>Women in mid-thirties without partner </li></ul>
  21. 21. Options for fertility preservation <ul><li>Should be tailored according to: </li></ul><ul><li>Patient ’ s age </li></ul><ul><li>Type of disease </li></ul><ul><li>Spread of the disease </li></ul><ul><li>Planned treatment </li></ul><ul><li>Time available </li></ul><ul><li>Whether she has a partner </li></ul>(Holzer Tan 2005)
  22. 22. Options for fertility preservation <ul><li>Ovarian protection: </li></ul><ul><li>Ovarian shielding </li></ul><ul><li>Ovarian transposition prior to local radiotherapy: </li></ul><ul><ul><li>reduces dose to 5-15% </li></ul></ul><ul><ul><li>patients <40 </li></ul></ul><ul><ul><li>Laparoscopy </li></ul></ul><ul><ul><li>Location depends on the planned radiation. </li></ul></ul><ul><ul><li>Does not protect against chemotherapy. </li></ul></ul>(Tulandi 2004)
  23. 23. Options for fertility preservation <ul><li>GnRH agonist acts to protect gonads during chemotherapy by preferentially steering cells into less active cell cycle stage with decline in response to chemotherapeutic agents </li></ul><ul><ul><li>Simulating pre-puberty. </li></ul></ul><ul><ul><li>Direct effect? </li></ul></ul><ul><ul><li>Decreased perfusion? </li></ul></ul><ul><li>Young patients. </li></ul><ul><li>(Blumenfeld 2007 ,Huser 2008) </li></ul>
  24. 24. Options for fertility preservation <ul><li>3 meta-analyses were published: </li></ul><ul><li>GnRHa are effective in preserving ovarian function and in reducing amenorrhoea (Clowse 2009, Ben Aharon 2010) </li></ul><ul><li>only prospective randomized studies: </li></ul><ul><ul><li>odds ratio of 3.5 favouring the use of GnRHa . </li></ul></ul><ul><ul><li>Higher rates of resumption of menses and ovulation </li></ul></ul><ul><ul><li>No improvement of pregnancy rates (Bedaiwy 2010) </li></ul></ul>
  25. 25. Options for fertility preservation <ul><li>The evidence that GnRHa has a protective effect on the ovaries is becoming more established. </li></ul><ul><li>the final conformation is still awaited. </li></ul><ul><li>GnRH antagnist – faster desensitization. </li></ul><ul><li>Flare up effect; combined treatment? (Mardesik 2004 von Wolff 2011) </li></ul><ul><li>The GnRHa could be used to induce ovulation in a stimulated cycle. </li></ul><ul><li>Reduced tumour cell sensitivity to chemo in E+ cases ? </li></ul>
  26. 26. Options for fertility preservation <ul><li>Apoptosis inhibition: </li></ul><ul><li>Ceramide – 2 nd messenger signals apoptosis </li></ul><ul><li>Sphingosine 1 phosphate (S1P) ceramid antagonist </li></ul><ul><li>Interesting and promising; still far from clinical implementation </li></ul><ul><li>(Morita, Paris, Perez, Tilly et al 1999,2000, 2002) </li></ul>
  27. 27. Cryopreservation for fertility preservation <ul><li>Transplantation of whole intact ovary by vascular anastomosis </li></ul><ul><li>Wang et al Nature 2002; </li></ul><ul><li>Imhof et al 2006; Bedaiwy et al 2007 </li></ul><ul><li>Huge technical challenge, perfusion of the cryoprotectant </li></ul><ul><li>In theory, risk of cancer cell transmission </li></ul>
  28. 28. Options for fertility preservation: Cryopreservation of ovarian tissue <ul><li>Available for pre- and post-puberty patients </li></ul><ul><li>Hundreds to thousands of primordial follicles may be preserved. </li></ul><ul><li>No medical delay. </li></ul><ul><li>No ovarian stimulation. </li></ul><ul><li>Does not require a male partner </li></ul><ul><li>At least 2 surgical procedures ( + IVF) </li></ul><ul><li>Anesthesia- risks </li></ul><ul><li>Theoretic risk of neoplastic cells in transplanted tissue – recurrence? </li></ul>
  29. 29. Risk of presence of neoplastic cells in the transplanted tissue <ul><li>Subclinical involvement of Hodgkin ’ s Lymphoma has not been identified in ovarian tissue (Seshadri Gook et al 2006) </li></ul><ul><li>detection of Hodgkin lymphoma within ovarian tissue taken at the time of harvest for cryopreservation . (Bittinger 2011) </li></ul><ul><li>58 patients with hematological malignancies underwent ovarian tissue cryopreservation </li></ul><ul><ul><li>after thawing, markers to detect minimal residual disease used </li></ul></ul><ul><ul><li>real-time RT-PCR positive in one patient with CML. </li></ul></ul><ul><ul><li>this alarming result avoided tissue transplantation (Meirow et al 2008) </li></ul></ul><ul><li>Positive markers of CML and AML in cryopresrved harvested ovarian tissue (Dolmans 2010) </li></ul>
  30. 30. Risk of presence of neoplastic cells in the transplanted tissue <ul><li>Other organ transplants: donor derived malignancy ( Kaufman 2002) </li></ul><ul><li>Extreme caution is warranted before we assume that we understand tumour biology well enough to estimate the risk of transmission of malignant cells in autotransplanted ovarian cortex. </li></ul><ul><li>BRCA 1&2 carriers - potential of developing ovarian cancer (Colgan 2001) </li></ul><ul><li>Prophylactic BSO, transplant ovarian fragments? </li></ul>
  31. 31. Options for fertility preservation: Cryopreservation of ovarian tissue <ul><li>Loss of follicles during transplantation and initial ischemia. Absence of inhibitory mechanism? Longevity of the graft? </li></ul><ul><li>13 pregnancies and live births reported : </li></ul><ul><ul><li>Donnez, Meirow * </li></ul></ul><ul><ul><li>Rosendahl * (6 pregnancies,3 live births, 2 women)/12 cases. </li></ul></ul><ul><ul><li>Demeestere (OTx2) </li></ul></ul><ul><ul><li>* IVF </li></ul></ul><ul><li>Bias due to selective reporting? </li></ul>
  32. 32. Options for fertility preservation: Cryopreservation of ovarian tissue <ul><li>Culture and IVM of primordial follicles: 2 step culture system: culture of tissue followed by isolation of follicles and culture. Or using 3D supportive matrix. Culturing to MII is the next chalange ( Abir et al. Histol. Histopatho 2006 Picton et al. Reproduction 2008, Tefler et al. Hum Rep. 2008, Woodruff 2009) </li></ul><ul><li>Suspension of isolated primordial follicles (Dolmans et al 2008) </li></ul><ul><li>Xenotransplantation: human ovarian tissue to SCID mice. Aberrant microtubule and chromatin patern. Transmission of pathogens, short life span ethical issues, and … ( Lucifero 2002, Kim 2001) </li></ul>
  33. 33. Embryo cryopreservation <ul><li>Integral part of IVF programs >25 years </li></ul><ul><li>Success rates 30-50% per embryo transfer, depending on the age at the time of oocytes retrieval. </li></ul><ul><li>Only well-established option of fertility preservation </li></ul><ul><li>Post pubertal patients. </li></ul><ul><li>Partner required </li></ul><ul><li>Donor sperm? </li></ul>
  34. 34. <ul><li>1 st live birth 1986 (Chen et al) </li></ul><ul><li>But: </li></ul><ul><li>oocytes vulnerable to freezing process </li></ul><ul><li>intracellular ice formation </li></ul><ul><li>membrane rupture, abnormal cortical granule reaction, zona hardening, meiotic spindle and cytoskeleton damage </li></ul><ul><li>1986-1997: 5 live births </li></ul>No male partner: Oocyte cryopreservation
  35. 35. <ul><li>Using PROH/sucrose slow freezing protocol and introduction of ICSI improved pregnancy rates (Porcu et al 1997) </li></ul><ul><li>Reported survival rates for mature oocytes (collected from stimulated ovaries) are 50-70% </li></ul><ul><li>Around 1000 live births slow freezing (Porcu et al 2009,Oktay et al 2006) </li></ul>No male partner: Oocyte cryopreservation
  36. 36. Oocyte vitrification <ul><li>Cryoprotectants in high concentration used to induce glasslike state, cell then rapidly frozen avoiding formation of intracellular ice </li></ul><ul><li>Kuleshova et al, 1999: survival rate 65%, PR/ET 21% </li></ul><ul><li>Yoon et al, 2003: survival rate 69%, implantation rate 6.4%, PR/ET 21.4% </li></ul><ul><li>Katayama et al, 2003: survival rate 94%, PR/ET 33% </li></ul>
  37. 37. Oocyte vitrification <ul><li>165 live births (Chian et al ASRM 2007: McGill Reproductive Center in Canada, Instituto Mexicano de Infertilidad in Mexico and CECOLFES in Colombia) </li></ul><ul><li>400 healthy babies (Kuwayama 2007) </li></ul><ul><li>Vitrification is emerging to be a better technique. </li></ul>
  38. 38. McGill vitrification tool, Cryoleaf Equilibration medium: Vitrification medium:
  39. 39. Oocyte vitrification: The McGill experience 38 Patients 31.5 ± 0.5 Mean age 463 (12.2 ± 0.9) Oocytes vitrified and thawed (mean t ±SEM) 383 (81.4 ± 3.7) Oocytes survived (mean % ±SEM) 287 (75.6 ± 3.7) Oocytes fertilized (mean % ±SEM) 133 (3.5 ± 0.2) Embryos transferred (mean ±SEM) 25/133 (19.1 ± 4.2) Implantation per embryo (mean % ±SEM) 17 (44.7) Clinical pregnancy rate per cycle (%) 3 Ongoing pregnancy 7 Singleton pregnancies 5 Twin pregnancies 1 Triplet pregnancies 13 Live births 20 Newborns
  40. 40. Embryo or oocyte cryopreservation after ovarian stimulation <ul><li>Pregnancies reported are result of fertilization of frozen/thawed oocytes collected after ovarian stimulation </li></ul><ul><li>However: </li></ul><ul><ul><li>time interval needed for ovarian stimulation 2-6 weeks. </li></ul></ul><ul><ul><li>Starting during menstruation </li></ul></ul><ul><ul><li>Time may not be available for cancer patients </li></ul></ul><ul><ul><li>Recent studies: stimulation luteal phase. (Von Wolff 2009, Sonmezer 2011) </li></ul></ul><ul><ul><li>ovarian stimulation associated with high estrogen levels which may not be safe in cases of hormone sensitive tumors such as breast cancer </li></ul></ul><ul><ul><li>Estrogens may have an indirect mitogenic effect on receptor negative cancers. (Gupta PB 2006) </li></ul></ul>
  41. 41. Embryo or oocyte cryopreservation after ovarian stimulation <ul><li>Aromatase inhibitor + FSH: </li></ul><ul><li>letrozole started 2 days before FSH administration, then given concomitantly, no increased risk of relapse ( Oktay 2005, 2007, Azim 2008) </li></ul><ul><li>Lower estradiol levels </li></ul><ul><li>does not totally avoid stimulation </li></ul><ul><li>Early follicular start of treatment. </li></ul><ul><li>More studies are needed </li></ul>
  42. 42. Collection of immature oocytes from unstimulated ovaries <ul><li>Pincus, J Exp Med 1935; Edwards, Nature, 1965,1969. </li></ul><ul><li>Cha et al,1991: Immature oocyte laparotomy for oocyte donation </li></ul><ul><li>Trounson et al, 1994: IVM: vaginal collection of immature oocytes, for PCO related infertility </li></ul>
  43. 43. IVM results 2009—PCOS & PCO Reinblatt 2010
  44. 47. Mature oocytes at oocyte collection in IVM cycles 8mm 12mm 14mm
  45. 48. Vitrification of IVM oocytes? <ul><li>Could oocytes collected from unstimulated ovaries, matured in vitro, then vitrified survive thawing and be fertilized? </li></ul><ul><li>Could transfer of these embryos result in a viable pregnancy ? </li></ul>
  46. 49. Holzer et al ESHRE 2007 Vitrification of IVM oocytes No. of patients 20 Mean age 30.7 ±3.7 No. of mature oocytes retrieved 7 No. of immature oocytes retrieved 295 Mean oocyte maturation rate (%) 67.9+4.1 No. of oocytes vitrified and thawed 215 No. of oocytes survived (mean % + SEM ) 148 (67.5 + 5.8) No. of oocytes fertilized (mean % + SEM) 96 (64.2 + 4.5) No. of embryos transferred (median; range) 64 (3.2; range 1 - 6) No. of implantations (mean % + SEM) 5 (10.3 + 5.7) No. of clinical pregnancies (%) 4 (20.0) No. of live births (%) 4 (20)
  47. 50. Conclusions <ul><li>Vitrification of in-vitro matured oocytes collected from unstimulated ovaries followed by later thawing and fertilization can result in successful pregnancies and live births </li></ul>
  48. 51. Conclusions <ul><li>Preliminary results </li></ul><ul><li>20 patients, all with PCO </li></ul><ul><li>20% pregnancy rate (vs. 35% in “Fresh IVM” ) </li></ul><ul><li>Lower implantation rate (10.8% vs. 14.4%) </li></ul><ul><li>Learning curve? </li></ul>
  49. 52. Conclusions <ul><li>Collection of immature oocytes from unstimulated ovaries followed by IVM and vitrification of mature oocytes could be offered to patients with hormone-sensitive disease and/or when there is not enough time to stimulate ovaries </li></ul><ul><ul><li>no risk of aggravating disease </li></ul></ul><ul><ul><li>no theoretic risk of re-instituting metastatic malignant disease </li></ul></ul><ul><ul><li>does not require same amount of time as that needed for ovarian stimulation, no need to wait for next cycle </li></ul></ul>
  50. 53. When ovarian tissue is being harvested <ul><li>Additional strategy of fertility preservation combines ovarian tissue cryobanking with retrieval of immature oocytes from excised ovarian tissue, followed by in vitro maturation (IVM) and vitrification (Huang, Tulandi, Holzer, Tan, Chian Fertil Steril 2007) </li></ul><ul><li>When surgery performed to remove ovarian tumor or for other therapeutic indications </li></ul>
  51. 54. Oocyte aspiration from excised ovarian tissue
  52. 55. Fertility preservation in prepubertal children <ul><li>Childhood and adolescence period of emotional and psychological instability; issues of sexuality, including fertility, are of particular importance </li></ul><ul><li>Depletion of primordial oocytes after gonadotoxic treatment proportional to size of oocyte pool </li></ul><ul><li>Younger patients have more oocytes; thus gonadal damage could seem to be less severe than in older patients </li></ul>
  53. 56. Fertility preservation in prepubertal children <ul><li>Global incidence of acute ovarian failure in childhood cancer survivors ranges from 6.3 to 12% (Bakker 2004) </li></ul><ul><li>In Childhood Cancer Survivor Study ;the relative risk for survivors of ever being pregnant was 0.81 (Green DM 2009) </li></ul><ul><li>Very few treatments benefit younger patients at risk of infertility after treatment </li></ul>
  54. 57. Fertility preservation in prepubertal children; Ovarian tissue cryobanking <ul><li>Primary method of fertility preservation for prepubertal girls </li></ul><ul><li>One ovary removed from 47 patients aged 0.1-14 y (median: 5) </li></ul><ul><li>Ovarian tissue fragments frozen </li></ul><ul><ul><li>strong inverse correlation found between age and follicular density </li></ul></ul><ul><ul><li>none of the cases had visible ovarian tumour components (Poirot 2007) </li></ul></ul><ul><li>58 patients 0.8-15.8 years, underwent ovarian </li></ul><ul><li>tissue cryopreservation. </li></ul><ul><ul><li>1 case of ovarian lymphoma infiltration (Jadoul 2010) </li></ul></ul>
  55. 58. Fertility preservation in prepubertal children: Combined approach <ul><li>Unilateral oophorectomy: 19 patients aged 5-20 years (median 15 yrs.) </li></ul><ul><li>Antral follicles aspirated, average no. of oocytes: 9 (0-37) </li></ul><ul><ul><li>GV oocytes – IVM </li></ul></ul><ul><ul><li>mature oocytes – frozen </li></ul></ul><ul><li>Ovarian tissue – cryopreserved in fragments </li></ul><ul><li>(Revel 2008) </li></ul>
  56. 59. Fertility preservation in prepubertal children: Ovarian tissue cryobanking <ul><li>Reimplantation of ovaries cryopreserved before puberty not yet performed in either nonpubertal or pubertal recipients </li></ul><ul><li>Animal models: puberty and fertility restored (Sauvat 2008) </li></ul><ul><li>Removal of entire ovary, although strongly advocated by some, may not be recommended for pediatric patients in whom fertility outcome is often uncertain. </li></ul><ul><li>How much? Based on the risk of the planned treatment and the ovarian volume. </li></ul>
  57. 60. Fertility preservation in pre-pubertal children <ul><li>Fertility preservation should now be considered in children facing cancer treatment with high risk of gonadal toxicity, including high-dose chemotherapy and bilateral irradiation of gonads at toxic doses </li></ul><ul><li>Multidisciplinary team </li></ul>
  58. 61. Fertility preservation strategies offered at McGill Fertility Preservation Center Chemotherapy can be delayed and hormonal stimulation not contra indicated Chemotherapy cannot be delayed or hormonal stimulation to be avoided IVF Treatment In-vitro maturation of oocytes Male partner No male partner Embryo vitrification Oocyte vitrification Collection of immature oocytes from ovarian tissue Ovarian tissue cryopreservation Laparoscopic ovarian biopsy Mature oocytes
  59. 62. McGill Fertility Preservation Center: Catchment Area <ul><li>Greater Montreal </li></ul><ul><li>Quebec </li></ul><ul><li>Other Canadian provinces </li></ul><ul><li>USA </li></ul><ul><li>Trance Atlantic </li></ul><ul><li>Physicians: Oncology, Haematology, Radiation Oncology, Surgery, Paediatrics. </li></ul><ul><li>Nurses: nursing coordinators. </li></ul><ul><li>Non- medical professionals, self referrals </li></ul>
  60. 63. <ul><li>Available and accessible: ” next day appointment ” policy. </li></ul><ul><li>Reciprocal: referring physician should be available, take part in planning. </li></ul><ul><li>Counsellor onsite or available via phone, Skype, webcam </li></ul><ul><li>On-going collaboration, individual cases </li></ul><ul><li>By-pass, current “ road blocks ” of the medical system. </li></ul><ul><li>Medico legal issues </li></ul>Accessibility
  61. 64. Issues discussed with treating physician <ul><li>Treatment: drugs, dose. </li></ul><ul><li>Time frame- coordinate treatments and tests. </li></ul><ul><li>Survival? </li></ul><ul><li>Risks of: </li></ul><ul><ul><li>Stimulation </li></ul></ul><ul><ul><li>Collection </li></ul></ul><ul><ul><li>Anaesthesia. </li></ul></ul>
  63. 66. McGill Fertility Preservation Center <ul><li>183 women with various malignancies underwent oocyte retrieval </li></ul><ul><li>117 underwent oocyte retrieval without ovarian stimulation followed by IVM : </li></ul><ul><ul><li>71 IVM cycles with vitrification of oocytes </li></ul></ul><ul><ul><li>46 IVM cycles, matured oocytes fertilized, resulting embryos vitrified </li></ul></ul>
  64. 67. McGill Fertility Preservation Center <ul><li>66 women underwent ovarian stimulation: </li></ul><ul><ul><li>45 stimulation cycles, mature oocytes vitrified </li></ul></ul><ul><ul><li>21 stimulation cycles, mature oocytes fertilized and resulting embryos vitrified </li></ul></ul>
  65. 68. Disease Categories for those who Froze Oocytes/embryos mean age = 29.7, SD =±5.6 Type of Cancer N=183 Breast cancer 75 Hematological malignancies 47 Brain malignancies 15 Gynecological cancers 14 Sarcoma 11 Desmoid Tumour 5 Autoimmune disease 9 Melanoma 1 Colorectal cancer 5 GIT Malignancy 1
  66. 69. Conclusions <ul><li>Current methods of fertility preservation should be considered as investigational </li></ul><ul><li>Patients and their families should be advised about experimental nature of process </li></ul><ul><li>Cancer treatments should NOT be compromised </li></ul>
  67. 70. Conclusions <ul><li>Fertility preservation is of utmost importance to patients and families of patients undergoing potentially gonadotoxic treatment </li></ul><ul><li>We provide option to try to preserve fertility potential </li></ul><ul><li>This hope alone may help in struggle to overcome the disease </li></ul>
  68. 71. Proper counseling and shared decision making Fertility preservation center
  69. 72. Thank you
  70. 73. Fertility preservation for young patients with cancer Wallace et al. Lancet Oncology 2007
  71. 76. Fertility preservation for young patients with cancer Wallace et al. Lancet Oncology 2007